You just read:

Trovagene Announces Data from Acute Myeloid Leukemia (AML) Phase 1b/2 Trial of Onvansertib Chosen for Oral Presentation at ASH 2019 Annual Meeting

News provided by

Trovagene, Inc.

Nov 06, 2019, 09:00 ET